Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise McEwan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Medical Imaging and Radiation Oncology|March 7, 2019
Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancerLouise McEwan, Rhiannon McBean, John Yaxley, et al.
Journal of Clinical Imaging Science|November 16, 2020
Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate CancerRhiannon McBean, Anisa Kumari, Louise McEwan, et al.
Journal of Medical Imaging and Radiation Oncology|November 7, 2025
What Do Medical Oncologists Expect From PET/CT ReportsSepinoud Firouzmand, Paul Vasey, Louise McEwan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 6, 2003
The diagnostic role of dual femur bone density measurement in low-impact fracturesJoseph C H Wong, Louise McEwan, Naomi Lee, et al.
Prostate Cancer and Prostatic Diseases|August 1, 2019
The use of <sup>68</sup>Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapySheliyan Raveenthiran, John Yaxley, Troy Gianduzzo, et al.
BJU International|June 28, 2020
Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging <sup>68</sup> Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?Michael Y Chen, Anthony Franklin, John Yaxley, et al.
Asian Journal of Urology|February 5, 2024
The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[<sup>18</sup>F]fluoro-d-glucose positron emission tomography/computed tomography for non-prostate cancer-related pathology: A single centre retrospective studyAnthony Franklin, Troy Gianduzzo, Boon Kua, et al.
The Journal of Urology|January 24, 2019
Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with <sup>68</sup>Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node PathologyJohn W Yaxley, Sheliyan Raveenthiran, François-Xavier Nouhaud, et al.
BJU International|May 30, 2019
Risk of metastatic disease on <sup>68</sup> gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancerJohn W Yaxley, Sheliyan Raveenthiran, François-Xavier Nouhaud, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomyMatthew J Roberts, Andrew Morton, Nathan Papa, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Medical Imaging and Radiation Oncology|March 7, 2019
Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancerLouise McEwan, Rhiannon McBean, John Yaxley, et al.
Journal of Clinical Imaging Science|November 16, 2020
Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate CancerRhiannon McBean, Anisa Kumari, Louise McEwan, et al.
Journal of Medical Imaging and Radiation Oncology|November 7, 2025
What Do Medical Oncologists Expect From PET/CT ReportsSepinoud Firouzmand, Paul Vasey, Louise McEwan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 6, 2003
The diagnostic role of dual femur bone density measurement in low-impact fracturesJoseph C H Wong, Louise McEwan, Naomi Lee, et al.
Prostate Cancer and Prostatic Diseases|August 1, 2019
The use of <sup>68</sup>Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapySheliyan Raveenthiran, John Yaxley, Troy Gianduzzo, et al.
BJU International|June 28, 2020
Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging <sup>68</sup> Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?Michael Y Chen, Anthony Franklin, John Yaxley, et al.
Asian Journal of Urology|February 5, 2024
The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[<sup>18</sup>F]fluoro-d-glucose positron emission tomography/computed tomography for non-prostate cancer-related pathology: A single centre retrospective studyAnthony Franklin, Troy Gianduzzo, Boon Kua, et al.
The Journal of Urology|January 24, 2019
Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with <sup>68</sup>Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node PathologyJohn W Yaxley, Sheliyan Raveenthiran, François-Xavier Nouhaud, et al.
BJU International|May 30, 2019
Risk of metastatic disease on <sup>68</sup> gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancerJohn W Yaxley, Sheliyan Raveenthiran, François-Xavier Nouhaud, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomyMatthew J Roberts, Andrew Morton, Nathan Papa, et al.
Pageof 1